MicroIslet, Inc. Retains New York-Based Investor Relations Firm

MicroIslet, Inc. (MIIS.OB, http://www.microislet.com), a biotechnology company engaged in the, development and commercialization of transplantation therapies for diabetes has engaged the Investor Relations Group, Inc. (“IRG”), based in New York City, to serve as its new financial relations and corporate communications firm.

“MicroIslet’s mission is to dramatically improve the health and quality of life for people with insulin-dependent diabetes through the development of novel cell transplantation therapy,” said Michael J. Andrews, Chief Executive Officer of MicroIslet, Inc. “We believe our xenotransplantation approach and proprietary microencapsulation technology will provide a long-overdue cell transplantation solution for millions of diabetic patients worldwide. As we move forward with our vision and continue to grow, the Investor Relations Group will play an integral part in communicating MicroIslet’s message to the investment community and the media.”

IRG will strive to increase investor and industry awareness of MicroIslet, Inc. within the U.S. and world markets by introducing the company and its management to pre-qualified fund managers, analysts, and the media-at-large.

About The Investor Relations Group, Inc.

The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of Alternative Public Offering (APO) companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company’s website at www.investorrelationsgroup.com.

About MicroIslet, Inc.

MicroIslet is a biotechnology company engaged in the research, development, and commercialization of patented technologies, in the field of transplantation therapy for patients with insulin-dependent diabetes. MicroIslet has licensed several technologies from Duke University Medical center for the isolation, culture, storage, and encapsulation (microencapsulation) of insulin-producing islet cells from porcine sources. These proprietary methods are among advances in the field of transplantation that may enable diabetic patients to become free from insulin injections. MicroIslet’s ultimate goal is to offer a solution towards a cure for diabetes worldwide.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including MicroIslet’s need to raise substantial additional funds in order to fund its new strategy and continue as a going concern, the risks and uncertainties inherent in medical treatment discovery, development and commercialization, the risks and uncertainties associated with MicroIslet’s early stage xenotransplantation technologies, the risks and uncertainties of governmental approvals and regulation, including foreign government approvals for clinical trials outside the United States, dependence on a sole source supplier of animal parts and a sole source manufacturer of encapsulated islets for pre-clinical and clinical studies, the risks that MicroIslet’s competitors will develop or market technologies or products that are more effective or commercially attractive than MicroIslet’s products, and other risks detailed from time to time in MicroIslet’s most recent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. MicroIslet disclaims any intent or obligation to update these forward-looking statements.

Additional information about MicroIslet can be found at http://www.microislet.com.